Portal Vein Doppler Is a Sensitive Marker for Evaluating Venous Congestion in End-Stage Kidney Disease.

Joseph R Pare, Jean M Francis, Aala Jaberi, Eduardo R Argaiz, Melinda M Tonelli, Erika Hooker, Helena Kurniawan, Krithika M Muruganandan

Journal: Cardiorenal medicine 2024;14(1):375-384

PMID: 38897186

Abstract

INTRODUCTION

Determining ultrafiltration volume in patients undergoing intermittent hemodialysis (IHD) is an essential component in the assessment and management of volume status. Venous excess ultrasound (VExUS) is a novel tool used to quantify the severity of venous congestion at the bedside. Given the high prevalence of pulmonary hypertension in patients with end-stage kidney disease (ESKD), venous Doppler could represent a useful tool to monitor decongestion in these patients.

METHODS

This is a prospective observational study conducted in ESKD patients who were admitted to the hospital requiring IHD and ultrafiltration. Inferior vena cava maximum diameter (IVCd), portal vein Doppler (PVD), and hepatic vein Doppler (HVD) were performed in all patients before and after a single IHD session.

RESULTS

Forty-one patients were included. The prevalence of venous congestion was 88% based on IVCd and 63% based on portal vein pulsatility fraction (PVPF). Both mean IVCd and PVPF displayed a significant improvement after ultrafiltration. The percent decrease in PVPF was significantly larger than the percent decrease in IVCd. HVD alterations did not significantly improve after ultrafiltration.

CONCLUSIONS

Our study revealed a high prevalence of venous congestion in hospitalized ESKD patients undergoing hemodialysis. After a single IHD session, there was a significant improvement in both IVCd and PVPF. HVD showed no significant improvement with one IHD session. PVPF changes were more sensitive than IVCd changes during volume removal. This study suggests that, due to its rapid response to volume removal, PVD, among the various components of the VExUS grading system, could be more effective in monitoring real-time decongestion in patients undergoing IHD.

© 2024 The Author(s). Published by S. Karger AG, Basel.

Address: Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA.; Emergency Department, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts, USA.; Departamento de Nefrología y Metabolismo Mineral, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.; Tecnológico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Mexico City, Mexico.; Emergency Department, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts, USA.; Maisonneuve-Rosemont Hospital Research Center, University of Montreal, Montreal, Québec, Canada.; Renal Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.